#Israel #Tel Aviv #financial results #Q3 2025 #Israel Corp

Overview of Israel Corporation's Third Quarter of 2025

Israel Corporation Ltd. (TASE: ILCO) has recently revealed its financial results for the third quarter ending September 30, 2025. This report outlines significant financial figures that highlight the company's current performance and liquidity position.

Financial Performance

In Q3 2025, Israel Corporation reported a net profit of $46 million for its shareholders, slightly down from $49 million in the same quarter the previous year. This decline is partially attributed to changes in the company’s income contributions from various segments, notably from ICL (Israel Chemicals Ltd.) and Prodalim.

Selected financial highlights for Q3 include:

• - ILCO's share in ICL profit stood at $51 million, an increase from $50 million year-over-year.
• - The contribution from Prodalim, while modest, rose to $1 million, recovering from a loss in the previous quarter.
• - Amortization costs associated with excess costs in held companies increased to $3 million from $1 million in the previous year, indicating higher operational costs.
• - Costs attributed to financing, general administration, and other services at the headquarters also grew, reaching $3 million compared to $1 million last year.

Despite these challenges, ILCO maintained a strong liquidity position reflecting operational resilience amid fluctuating market conditions.

Liquidity and Cash Position

As of September 30, 2025, Israel Corporation’s total financial liabilities amounted to approximately $660 million. Nevertheless, the company boasted investments in liquid assets totaling $695 million, of which $8 million are currently pledged deposits. The net cash position at this date reached $45 million, an improvement from $26 million noted in June 2025, highlighting positive cash flow trends in the interim.

Asset Overview

The total assets reflecting ILCO's equity position stand impressively at $3,794 million, bolstered primarily by its holdings in major subsidiaries:

• - ICL’s market value is around $3.55 billion, possessing about 567 million shares.
• - Prodalim, while carrying a cost basis of $118 million, is strategically important to the company’s agricultural initiatives.
• - Other significant holdings include AKVA Group with a market value of $62 million, alongside minor assets valued at $19 million.

The substantial valuation of ICL remains pivotal for ILCO, characterized by its robust market performance and significant shareholding.

Company Insights

Israel Corporation operates in diverse sectors with a prominent focus on chemicals and agriculture, specifically through its investments in ICL and Prodalim. The company consistently aligns its strategies to meet market demands and leverage its portfolio for sustained growth. For full transparency, the financial reports can be accessed publicly through the Tel Aviv Stock Exchange or their official website.

Conclusion

In summary, Israel Corporation's Q3 results for 2025 portray a resilient financial standing marked by steady profits, a solid liquidity position, and an extensive asset base. Despite encountering some challenges regarding costs, the ongoing investment strategy and market positioning ensure the company is well-placed to navigate future uncertainties. This report details the critical aspects of ILCO's current standings and offers insights into its operational effectiveness within the competitive landscape.